Related Experiment Video

Updated: Apr 25, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

LDL cholesterol: controversies and future therapeutic directions

Paul M Ridker¹

¹Harvard Medical School, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital Boston, MA, USA.

Lancet (London, England)

|August 19, 2014

Insights

High LDL cholesterol increases cardiovascular risk. Novel therapies, including monoclonal antibodies, are rapidly translating genetic insights into clinical practice to assess safe and effective LDL cholesterol reduction.

Area of Science:

Cardiovascular Medicine
Genetics
Pharmacology

Background:

Elevated low-density lipoprotein (LDL) cholesterol is a primary driver of cardiovascular events.
Statins effectively reduce hyperlipidemia but controversies persist regarding LDL measurement, screening, and treatment targets.
Genetic defects affecting the LDL receptor highlight its critical role in inherited hyperlipidemias.

Purpose of the Study:

To address ongoing controversies in LDL cholesterol management, including measurement, screening, and drug efficacy.
To evaluate novel therapies, particularly monoclonal antibodies, for their ability to significantly lower LDL cholesterol.
To determine the safety and efficacy of aggressive LDL cholesterol lowering and its impact on atherothrombotic complications.

Main Methods:

Review of biological, genetic, and epidemiological data supporting LDL cholesterol's role in cardiovascular disease.
Analysis of evidence from randomized trials on statin therapy and emerging LDL-lowering drugs.
Assessment of ongoing Phase 3 trials involving over 60,000 patients evaluating monoclonal antibodies targeting the LDL receptor lifecycle.

Main Results:

Statins have proven effective in reducing the population burden of hyperlipidemia.
Novel therapies, including monoclonal antibodies, show potential for substantial LDL cholesterol reduction beyond statin therapy.
Large-scale trials are underway to investigate the safety and efficacy of achieving very low LDL cholesterol levels.

Conclusions:

Despite established benefits, controversies remain regarding optimal LDL cholesterol management strategies.
Rapid translation of genetic discoveries into novel therapies like monoclonal antibodies is transforming hyperlipidemia treatment.
Ongoing research aims to define the safety, efficacy, and long-term benefits of aggressive LDL cholesterol lowering for cardiovascular event prevention.

Read full analysis

Abstract:

Lifelong exposure to raised concentrations of LDL cholesterol increases cardiovascular event rates, and the use of statin therapy as an adjunct to diet, exercise, and smoking cessation has proven highly effective in reducing the population burden associated with hyperlipidaemia. Yet, despite consistent biological, genetic, and epidemiological data, and evidence from randomised trials, there is controversy among national guidelines and clinical practice with regard to LDL cholesterol, its measurement, the usefulness of population-based screening, the net benefit-to-risk ratio for different LDL-lowering drugs, the benefit of treatment targets, and whether aggressive lowering of LDL is safe. Several novel therapies have been introduced for the treatment of people with genetic defects that result in loss of function within the LDL receptor, a major determinant of inherited hyperlipidaemias. Moreover, the usefulness of monoclonal antibodies that extend the LDL-receptor lifecycle (and thus result in substantial lowering of LDL cholesterol below the levels achieved with statins alone) is being assessed in phase 3 trials that will enrol more than 60,000 at-risk patients worldwide. These trials represent an exceptionally rapid translation of genetic observations into clinical practice and will address core questions of how low LDL cholesterol can be safely reduced, whether the mechanism of LDL-cholesterol lowering matters, and whether ever more aggressive lipid-lowering provides a safe, long-term mechanism to prevent atherothrombotic complications.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Lipids: Dietary Sources and Requirements

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Articles linked to this work by shared authors, journal, and citation graph.

Genetic loci associated with circulating phospholipid trans fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium.

The American journal of clinical nutrition·2015

Efficient Bayesian mixed-model analysis increases association power in large cohorts.

Nature genetics·2015

Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.

Nature communications·2015

Dietary fatty acids modulate associations between genetic variants and circulating fatty acids in plasma and erythrocyte membranes: Meta-analysis of nine studies in the CHARGE consortium.

Molecular nutrition & food research·2015

No evidence for genome-wide interactions on plasma fibrinogen by smoking, alcohol consumption and body mass index: results from meta-analyses of 80,607 subjects.

PloS one·2015

Vitamin D-associated genetic variation and risk of breast cancer in the breast and prostate cancer cohort consortium (BPC3).

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2014

See all related articles